-
Stakeholder And Contact Window
Board of Directors
- Board Of Directors Information
- Remuneration
- Major Resolutions of Board Meetings
- Training Status
- BOD Performance Evaluation Report
- Information on the Elected Independent Directors
Directors concurrently serving as company officers not exceed one-third of the total number of the board members, and that an appropriate policy on diversity based on the company's business operations, operating dynamics, and development needs be formulated and include, without being limited to, the following two general standards:
1. Basic requirements and values: Gender, age, nationality, and culture.
2. Professional knowledge and skills: A professional background (e.g., law, accounting, industry, finance, marketing, technology), professional skills, and industry experience.
All members of the board shall have the knowledge, skills, and experience necessary to perform their duties. To achieve the ideal goal of corporate governance, the Board of Directors shall possess the following abilities:
1. Ability to make operational judgments.
2. Ability to perform accounting and financial analysis.
3. Ability to conduct management administration.
4. Ability to conduct crisis management.
5. Knowledge of the industry.
6. An international market perspective.
7. Ability to lead.
8. Ability to make policy decisions.
Currently, there are 6 directors and 4 independent directors in Lumosa's Board of Directors. They have experiences in financial accounting, biotechnology, medicine and business. The members have different professional backgrounds. The diversity policy of the board is implemented.
1. Basic requirements and values: Gender, age, nationality, and culture.
2. Professional knowledge and skills: A professional background (e.g., law, accounting, industry, finance, marketing, technology), professional skills, and industry experience.
All members of the board shall have the knowledge, skills, and experience necessary to perform their duties. To achieve the ideal goal of corporate governance, the Board of Directors shall possess the following abilities:
1. Ability to make operational judgments.
2. Ability to perform accounting and financial analysis.
3. Ability to conduct management administration.
4. Ability to conduct crisis management.
5. Knowledge of the industry.
6. An international market perspective.
7. Ability to lead.
8. Ability to make policy decisions.
Currently, there are 6 directors and 4 independent directors in Lumosa's Board of Directors. They have experiences in financial accounting, biotechnology, medicine and business. The members have different professional backgrounds. The diversity policy of the board is implemented.
| Position | Name | Education | Current Positions | Past Experiences |
| Chairman | Mr. Rong-Jin Lin | Ph.D (hon), College of Medicine, Taipei Medical University B.S., College of Pharmacy, Taipei Medical University |
Representative of Corporate Director and Chairman of Center Laboratories, Inc. Representative of Corporate Director and Chairman of Mycenax Biotech, Inc. Representative of Corporate Director of Adimmune Corp. Representative of Corporate Director of BioGend Therapeutics Co., Ltd. Representative of Corporate Director and Chairman of glac Biotech Co., Ltd. Representative of Corporate Director and Chairman of BioEngine Capital, Inc. Representative of Corporate Director and Chairman of BioEngine Technology Development, Inc. Representative of Corporate Director of BRIM Biotechnology, Inc. Chairman of Royal Foods Co., Ltd. Representative of Corporate Director and Chairman of Ausnutria Dairy (Taiwan) Nutrition & Health Corp. Representative of Corporate Director and Chairman of Youluck International, Inc. |
Chairman and General Manager, TTY Biopharm Company Limited Chairman, PharmaEngine, Inc. |
| Director | Mr. Wann-Lai Cheng | BBA, Fu Jen Catholic University, Taiwan | General Manager of Taiwan Calsonic Co., Ltd. | Chairman of Ever Link Co. Chairman of Browave Holding Inc. Independent Director of Powertech Technology Inc. Director of Center Laboratories, Inc. Representative of Corporate Director of Mycenax Biotech, Inc. Representative of Corporate Director of glac Biotech Co., Ltd. Representative of Corporate Director of BioEngine Capital, Inc. Representative of Corporate Director of BioEngine Technology Development, Inc. Chairman of Lumosa Therapeutics Co., Ltd. (Caymen) |
| Director | Bioengine Technology Development Inc. | |||
| Director | Dr. Chong-Hao Tsai | Ph.D., Clinical Medicine, Chang Gung University, Taiwan B.Med., China Medical University, Taiwan |
Director of Medicial Research Department, China Medical University Research fellow, movement disorder and neuro-electrophysiologics, Royal Adelaide Hospital, Australia Attending physician, Neurology Movement Disorder Center, Chang Gung Memorial Hospital, Linkou Branch |
Director, Department of Neurology, China Medical University Hospital Director, Neurology Laboratory, Department of Neurology, China Medical University Hospital Dean, School of Medicine, China Medical University Director, Taiwan Movement Disorder Society Executive Director, Asia Pacific Region, International Parkinson and Movement Disorder Society |
| Director | Shun Cheng Pharmaceutical Co. | |||
| Director | Ms. Hsueh-Ling Wang | M.S., Department of Accounting, National Chengchi University, Taiwan B.S., Department of Accounting, Tamkang University, Taiwan |
Representative of Corporate Director and Vice Chairperson of Sun Ten Pharmaceuticals Representative of Corporate Director of Sun Ten Natureceutica Co., Ltd. Chairperson of He Li Chang Yeh Limited Representative of Corporate Director and Chairperson of Sunbeaus Ltd. Co. Director of Shun Tian International Investment Consulting Co., Ltd. Representative of Corporate Director Herbiotek Co., Ltd. |
Chief, National Taxation Bureau of Taipei, Ministry of Finance President, Sun Ten Pharmaceuticals Director, Lumosa Therapeutics Co., Ltd. Supervisor of King Anticancering Biotech Co., Ltd. |
| Independent Director | Dr. Chih-Hsiung Wu | Ph.D, Dokkyo Medical University, Tochigi, Japan B.Med., Taipei Medical College, Taiwan |
Representative of Corporate Director of Medeon Biodesign Co., Ltd. CEO of Hsing Tian Kong Foundation Medical Mission Superintendent of En Chu Kong Hospital Chair Professor, Taipei Medical University Director, Taipei Medical University |
Superintendent, Taipei Medical University Hospital Superintendent, Shuangho Hospital, Ministry of Health and Welfare Director, Taiwan Surgical Association |
| Independent Director | Dr. Josephine Shen | Ph.D., Department of Chemistry, Lehigh University, Pennsylvania, USA | Independent Director, BioGend Therapeutics, Co., Ltd. Director, Formosa Pharmaceuticals, Inc. Partner, Vivo Capital Advisory Committee, National Institutes of Health, Taiwan Executive Director Taiwan Bio Industry Organization |
Co-founder, ScinoPharm Taiwan, Ltd. President, Chairperson and COO of ScinoPharm Taiwan, Ltd. Founder of Biotech Industrial Academy President of Shennong International Corporate Vice President, Syntex Laboratories Site Manager, Monsatno Industrial Chemical Division, Superintendent, Quality Engineering, Monsanto Electronics Materials Division Independent Director, Crown Bioscience International Director, TWI Pharmaceuticals, Inc. Director, Reber Genetics Co., Ltd. |
| Independent Director | Mr. Chih-Yung Chin | M.Acc., Case Western Reserve University, Ohio, USA B. Int'l Trade, Tamkang University, Taiwan |
Director of Leading Change International CPA Firm Independent Director of Space Shuttle Hi-Tech Co., Ltd. |
Senior Manager, CPA, Pan Asia International & Co. |
